Pembrolizumab is
Pembrolizumab and Nevolumab are monoclonal antibodies against PDL1 receptor used in BRAF -ve malignant melanoma.
CTLA4 inhibitor
Monoclonal antibody against PDL1 receptor
Monoclonal antibody against PD1 ligand
Monochonal antibody against CDK416